Brink Pharmaceuticals initiates Usher in 2 clinical inquisition of TH-302 in patients with first place straighten pancreatic cancer
Start Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that it has initiated a multi-center, randomized, controlled, crossover Status 2 clinical trying out of TH-302 in set with gemcitabine in patients with first off sales pitch pancreatic cancer. TH-302 is a proprietary tumor exacting Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia.
"TH-302 has been investigated in Off 1/2 clinical trials in exceeding 300 patients, including 50 patients with pancreatic cancer. This contemporary randomized clinical judicial proceeding is designed to settle the awe-inspiring results that were observed and recently reported in patients with pancreatic cancer," said Dr. Mitesh Borad, Associate Head at the Mayo Clinic in Arizona and a clinical investigator since this and whilom trials of TH-302. "Given the encouraging results observed to engagement in the Phase1/2 trials with TH-302, I am looking well-developed to continuing our participation as TH-302 enters this next work in of clinical development."
Clinical Testing Devise
Help-Medical.net finds at this phrases:
- tivozanib 2010 patent
- you zizz .com
- Cancer Center in Cleveland NKTR-102
- CGEN 15001
- Semuloparin
- elise heon
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
